{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:17:44Z","timestamp":1790968664351,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018973","name":"Lovely Professional University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bioorg.2023.107029","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T21:55:08Z","timestamp":1702158908000},"page":"107029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Synthesis, molecular docking and biological evaluation of 1,2,4-oxadiazole based novel non-steroidal derivatives against prostate cancer"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8407-4693","authenticated-orcid":false,"given":"Shubham","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-2749","authenticated-orcid":false,"given":"Pankaj","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2023.107029_b0005","first-page":"153","article-title":"Current challenges in health economic modeling of cancer therapies: a research inquiry","volume":"7","author":"Miller","year":"2014","journal-title":"Am. Health Drug Benefits"},{"issue":"2","key":"10.1016\/j.bioorg.2023.107029_b0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"10.1016\/j.bioorg.2023.107029_b0015","series-title":"Anatomy of the prostate gland and surgical pathology of prostate cancer","first-page":"1","author":"Hammerich","year":"2009"},{"issue":"4","key":"10.1016\/j.bioorg.2023.107029_b0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1272\/jnms.JNMS.2018_85-37","article-title":"A case of primary malignant lymphoma of the prostate gland presenting as right lower back pain and dysuria","volume":"85","author":"Yasuoka","year":"2018","journal-title":"J. Nippon Med. Sch."},{"issue":"12","key":"10.1016\/j.bioorg.2023.107029_b0025","first-page":"1269","article-title":"Treatment options for localized prostate cancer","volume":"59","author":"Keyes","year":"2013","journal-title":"Can. Fam. Physician"},{"issue":"4","key":"10.1016\/j.bioorg.2023.107029_b0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.disamonth.2014.02.003","article-title":"A review of the current epidemiology and treatment options for prostate cancer","volume":"60","author":"Saman","year":"2014","journal-title":"Dis. Mon."},{"key":"10.1016\/j.bioorg.2023.107029_b0035","doi-asserted-by":"crossref","unstructured":"Dunn, M. W.; Kazer, M. W. Prostate cancer overview. In Seminars in oncology nursing, 2011; Elsevier: Vol. 27, pp 241-250.","DOI":"10.1016\/j.soncn.2011.07.002"},{"issue":"10","key":"10.1016\/j.bioorg.2023.107029_b0040","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1525-1497.2000.90842.x","article-title":"Treatment decisions for localized prostate cancer","volume":"15","author":"Holmboe","year":"2000","journal-title":"J. Gen. Intern. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2023.107029_b0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00261959","article-title":"Study of the effect of an anti-androgen (Oxendolone) on experimentally induced canine prostatic hyperplasia","volume":"16","author":"Okada","year":"1988","journal-title":"Urol. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2023.107029_b0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0094-0143(21)01398-7","article-title":"Use of cyproterone acetate in prostate cancer","volume":"18","author":"Goldenberg","year":"1991","journal-title":"Urol. Clin. N. Am."},{"issue":"3","key":"10.1016\/j.bioorg.2023.107029_b0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41391-020-0220-8","article-title":"Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study","volume":"23","author":"Beckmann","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"6","key":"10.1016\/j.bioorg.2023.107029_b0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/17843286.2018.1543827","article-title":"Abiraterone and spironolactone in prostate cancer: a combination to avoid","volume":"74","author":"Dhondt","year":"2019","journal-title":"Acta Clin. Belg."},{"issue":"8","key":"10.1016\/j.bioorg.2023.107029_b0065","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s11095-006-9024-3","article-title":"Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands","volume":"23","author":"Gao","year":"2006","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.bioorg.2023.107029_b0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003088-199834050-00005","article-title":"Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer","volume":"34","author":"Mahler","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.bioorg.2023.107029_b0075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10637-021-01202-6","article-title":"A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer","volume":"40","author":"Maurice-Dror","year":"2022","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.bioorg.2023.107029_b0080","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0968-0896(01)00421-7","article-title":"Novel non-steroidal\/non-anilide type androgen antagonists with an isoxazolone moiety","volume":"10","author":"Ishioka","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107029_b0085","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.phymed.2018.03.054","article-title":"The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide","volume":"46","author":"Stanis\u0142awska","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2023.107029_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2011.11.007","article-title":"A comparative assessment of \u03b1-lipoic acid N-phenylamides as non-steroidal androgen receptor antagonists both on and off gold nanoparticles","volume":"40","author":"Henderson","year":"2012","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2023.107029_b0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/molecules26010056","article-title":"Synthesis and biological evaluation of bicalutamide analogues for the potential treatment of prostate cancer","volume":"26","author":"Kandil","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2023.107029_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejmech.2019.01.054","article-title":"Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists","volume":"167","author":"Kandil","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2023.107029_b0105","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.bmcl.2012.01.059","article-title":"1, 2, 4-Oxadiazoles: A new class of anti-prostate cancer agents","volume":"22","author":"Khatik","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.bioorg.2023.107029_b0110","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/j.bmcl.2016.04.058","article-title":"Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents","volume":"26","author":"Mochona","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bioorg.2023.107029_b0115","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.bmcl.2015.03.001","article-title":"Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1, 3, 4-oxadiazole derivatives","volume":"25","author":"El-Din","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.107029_b0120","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.freeradbiomed.2019.01.003","volume":"134","author":"Xu","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bioorg.2023.107029_b0125","first-page":"81","article-title":"Ferrocene functionalized endocrine modulators as anticancer agents","author":"Hillard","year":"2010","journal-title":"Med. Organomet. Chem."},{"key":"10.1016\/j.bioorg.2023.107029_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112512","article-title":"The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader","volume":"204","author":"Xie","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107029_b0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.taap.2016.07.018","article-title":"TBECH, 1, 2-dibromo-4-(1, 2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer","volume":"307","author":"Kharlyngdoh","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"13","key":"10.1016\/j.bioorg.2023.107029_b0140","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/molecules24132470","article-title":"Amidoximes and oximes: Synthesis, structure, and their key role as NO donors","volume":"24","author":"Sahyoun","year":"2019","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.bioorg.2023.107029_b0145","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ejmech.2011.01.015","article-title":"Synthesis of some novel 3-(1-(1-substitutedpiperidin-4-yl)-1H-1, 2, 3-triazol-4-yl)-5-substituted phenyl-1, 2, 4-oxadiazoles as antifungal agents","volume":"46","author":"Sangshetti","year":"2011","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2023.107029_b0150","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/jm501661f","article-title":"Structure\u2013activity relationship for the oxadiazole class of antibiotics","volume":"58","author":"Spink","year":"2015","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2023.107029_b0155","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1021\/acsmedchemlett.9b00379","article-title":"Structure\u2013activity relationship for the oxadiazole class of antibacterials","volume":"11","author":"Boudreau","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.107029_b0160","first-page":"S1","article-title":"Supplementary Material An efficient synthesis and antimicrobial evaluation of 5-alkenyl-and 5-styryl-1, 2, 4-oxadiazoles","volume":"7","author":"Tarasenkoa","year":"2018","journal-title":"ARKIVOC"},{"issue":"8","key":"10.1016\/j.bioorg.2023.107029_b0165","first-page":"1650","article-title":"miR-186 inhibits cell proliferation of prostate cancer by targeting GOLPH3","volume":"6","author":"Hua","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2023.107029_b0170","doi-asserted-by":"crossref","unstructured":"Bilir, E. K.; Tutun, H.; Sevin, S.; Kismali, G.; Yarsan, E. Cytotoxic effects of Rhododendron ponticum L. extract on prostate carcinoma and adenocarcinoma cell line (DU145, PC3). Kafkas \u00dcniversitesi Veteriner Fak\u00fcltesi Dergisi 2018, 24 (3).","DOI":"10.9775\/kvfd.2017.19219"},{"key":"10.1016\/j.bioorg.2023.107029_b0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-60761-411-1_4","article-title":"Identification of ROS using oxidized DCFDA and flow-cytometry","volume":"II","author":"Eruslanov","year":"2010","journal-title":"Adv. Protocols Oxidative Stress"},{"issue":"7","key":"10.1016\/j.bioorg.2023.107029_b0180","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2800","article-title":"Measurement of ROS in Caenorhabditis elegans using a reduced form of fluorescein","volume":"8","author":"Sarasija","year":"2018","journal-title":"Bio-Protocol"},{"key":"10.1016\/j.bioorg.2023.107029_b0185","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-60761-702-0_18","article-title":"Determination and detection of reactive oxygen species (ROS), lipid peroxidation, and electrolyte leakage in plants","author":"Jambunathan","year":"2010","journal-title":"Plant Stress Tolerance: Methods and Protocols"},{"issue":"16","key":"10.1016\/j.bioorg.2023.107029_b0190","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/S0960-894X(03)00575-4","article-title":"Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor","volume":"13","author":"Ishioka","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"18","key":"10.1016\/j.bioorg.2023.107029_b0195","doi-asserted-by":"crossref","first-page":"13648","DOI":"10.1074\/jbc.M611711200","article-title":"Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design","volume":"282","author":"Bohl","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2023.107029_b0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1573409914666181019165821","article-title":"In silico molecular docking study to search new SGLT2 inhibitor based on dioxabicyclo [3.2. 1] octane scaffold","volume":"16","author":"Kumar","year":"2020","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.bioorg.2023.107029_b0205","unstructured":"Kumar, S.; Arora, P.; Wadhwa, P.; Kaur, P. A Rationalized Approach to Design and Discover Novel Non-steroidal Derivatives through Computational Aid for the Treatment of Prostate Cancer. Current computer-aided drug design."},{"issue":"2","key":"10.1016\/j.bioorg.2023.107029_b0210","first-page":"135","article-title":"Drug designing in discovery studio","volume":"14","author":"Jejurikar","year":"2021","journal-title":"Asian J. Res. Chem."},{"key":"10.1016\/j.bioorg.2023.107029_b0215","unstructured":"Design, L. Pharmacophore and ligand-based design with Biovia Discovery Studio\u00ae. 2014."},{"issue":"2","key":"10.1016\/j.bioorg.2023.107029_b0220","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2023.107029_b0225","article-title":"Prediction is a balancing act: Importance of sampling methods to balance sensitivity and specificity of predictive models based on imbalanced chemical data sets","volume":"362","author":"Banerjee","year":"2018","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2023.107029_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.bioorg.2023.107029_b0235","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823006909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823006909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:52:40Z","timestamp":1758617560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823006909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":47,"alternative-id":["S0045206823006909"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.107029","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, molecular docking and biological evaluation of 1,2,4-oxadiazole based novel non-steroidal derivatives against prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.107029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107029"}}